All In Biotech

Drug Trial Radar · NCT07169552

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

A Multicenter, Single-arm, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of HC010 for Injection in the First-line Treatment of Advanced Non-small Cell Lung Cancer Positive for Programmed Death Ligand-1 (PD-L1)

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Dec 30, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
HC Biopharma Inc.Industry
Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)

Conditions

  • NSCLC

Interventions

  • HC010Drug

    HC010 Q3W intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 24months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.